"Although each rare disease impacts a small population, the rare disease population is estimated to be 10% of the total population, meaning 25-30 million Americans have at least one rare condition."
PRESIDENT AND CEO & CHIEF SCIENTIFIC OFFICER, VYANT BIO
"At Vyant Bio we are reinventing how drugs are discovered for complex neurological and neurodegenerative disorders by applying a human-first approach."
"AC Immune is combining diagnostics and therapeutics, and it has developed the tools to enable detection and clearance of specific pathological proteins underlying neurodegenerative diseases."
PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."
"While it's always easier to deny a certain service if you don't yet have the technical expertise in a particular area, in the long-term it is advantageous to explore the possibility of investing in that area with the customer."
"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."
"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.